The Board of Directors of Glenmark Pharmaceuticals Limited, in their meeting held on May 29, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. On a consolidated basis, the company reported a net profit after tax of 3,013.19 million for the quarter ended March 31, 2026, compared to a profit of 43.84 million in the corresponding quarter of the previous year and a profit of 4,032.28 million in the previous quarter.

Glenmark Pharmaceuticals Limited is a research-led, integrated global pharmaceutical company with a presence in Generics, Specialty, and OTC businesses. The company has established a significant global footprint with a portfolio of products across various therapeutic areas. The company’s recent financial performance has been influenced by various exceptional items, including legal settlements related to antitrust litigation in the U.S. and provisions made for inventory management and labor code changes.

In addition to financial results, the company announced leadership changes, including the early retirement of Mr. Harish Kuber from his position as Company Secretary and Compliance Officer, effective from the close of business hours on May 29, 2026. Ms. Rashmi Khandelwal has been appointed as the new Company Secretary and Compliance Officer, effective May 30, 2026, and brings over 17 years of experience in corporate governance and regulatory matters. Furthermore, Mr. Samir Kazi has been appointed as a Senior Management Personnel, designated as Executive Vice President & Head Legal, Compliance & IP, effective May 29, 2026.